AMENDMENT

Amendment to the Specification:

Please delete Tables I-A through V on pages 34-75 of the specification and replace them with the following Tables I-A through V:

Table I-A: 6-ACYL-BENZAZINONES AND 7-ACYL-BENZOTHIAZINONES

6-Acyl-benzoxazolinones, 6-acyl-benzothiazolinones, 6-acyl-benzoxazinones, 6-acyl-benzothiazinones and 7-acyl-benzothiazinones



Example	R_1	X	Y	Z	B	Molecule	F°C	Method
1a	H	O	-	H			260-261	B ($AlCl_3$/DMF)
2a	CH_3	O	-	H			202-204	B
3a	H	O	-	H			260-261	B
4a	CH_3	O	-	H			200-201	B
5a	CH_3	O	-	H			181-182	B
6a	CH_3	O	-	H			163-164	B

Table I-A (continued)-BENZAZINONES AND 7-ACYL-BENZOTHIAZINONES

6-Acyl-benzoxazolinones, 6-acyl-benzothiazolinones, 6-acyl-benzoxazinones, 6-acyl-benzothiazinones and 7-acyl-benzothiazinones



Example	R_1	X	Y	Z	B	Molecule	F°C	Method
7a	H	S	-	H			205-209	B
8a	CH_3	S	-	H			196-199	B
9a	CH_2CH_3	S	-	H			136-138	B
10a	H	CH_2	-	H			250-253	B
11a	H	O	CH_2	H			182-185	A. (PPA)

Table I-A (continued)-BENZAZINONES AND 7-ACYL-BENZOTHIAZINONES

6-Acyl-benzoxazolinones, 6-acyl-benzothiazolinones, 6-acyl-benzoxazinones, 6-acyl-benzothiazinones and 7-acyl-benzothiazinones



Example	R_1	X	Y	Z	B	Molecule	F°C	Method
12a	CH_3	O	CH_2	H			173-176	A.
13a	H	O	CH_2	H			280-283	B
14a	CH_3	O	CH_2	H			208-211	B
15a	H	S	CH_2	H			261-263	B
16a	CH_3	S	CH_2	H			179-180	B

Table I-A (continued)-BENZAZINONES AND 7-ACYL-BENZOTHIAZINONES

6-Acyl-benzoxazolinones, 6-acyl-benzothiazolinones, 6-acyl-benzoxazinones, 6-acyl-benzothiazinones and 7-acyl-benzothiazinones



Example	R_1	X	Y	Z	B	Molecule	F°C	Method
17a	H	O	-	H			169-170	A (PPA)
18a	CH_3	O	-	H			147-148	A.
19a	H	S	-	H			216-217	A
20a	CH_3	S	-	H			148-149	A
21a	CH_3	O	-	H			190-191	A

Table I-A (continued)-BENZAZINONES AND 7-ACYL-BENZOTHIAZINONES

6-Acyl-benzoxazolinones, 6-acyl-benzothiazolinones, 6-acyl-benzoxazinones, 6-acyl-benzothiazinones and 7-acyl-benzothiazinones



Example	R_1	X	Y	Z	B	Molecule	F°C	Method
22a	CH_3	S	-	H			176-177	A.
23a	H	S	-	H			260-265	B
24a	H	O	CH_2	H			281-282	B
25a	H	S	CH_2	H			194-196	B

Table I-B: 6-ACYL-BENZAZINONES

6-acyl-benzothiazolinones, 6-acyl- benzoselenazolinones



Example	R_1	X	Y	Z	B	Isomer	Molecule	F°C	Method
1	H	S	-	H		6		260-265	B ($AlCl_3$/DMF)
2	CH_2CH_3	S	-	H		6		148-152	N-alkyl
3	H	Se	-	H		6		230-232	B
4	CH_3	Se	-	H		6		205-210	B
5	CH_2CH_3	Se	-	H		6		130-135	N-alkyl

6	H	Se	-	H		6		241-245	B
7	CH_3	Se	-	H		6		151-155	N-alkyl
8	CH_2CH_3	Se	-	H		6		97-102	N-alkyl

TABLE II: 5 and 7-ACYL-BENZAZINONES

5-Acyl-benzoxazolinones, 7-acyl-benzoxazinones



Example	R_1	X	Y	Z	B	Molecule	F°C	Preparation
26a	H	O	-	H			250-253	2
27a	H	O	-	H			307-310	2
28a	H	O	-	6-OCH_3			224-226	2
29a	H	O	-	H			153-160	2
30a	CH_3	O	-	H			152-156	2
31a	CH_3	O	-	H			163-164	2

TABLE II (continued): 5 and 7-ACYL-BENZAZINONES
5-Acyl-benzoxazolinones, 7-acyl-benzoxazinones

32a	H	O	CH_2	H			210-213	3
33a	CH_3	O	CH_2	H			117-119	3

Table III-A: REDUCED DERIVATIVES
Hydroxyarylmethyl benzazinones



Example	R_1	X	Y	Z	B	Molecule	F°C
1b	H	O	-	H			195-197
2b	CH_3	O	-	H			145-146
3b	H	O	-	H			130-131
4b	CH_3	O	-	H			83-85
5b	CH_3	O	-	H			243-245

Table III-A (continued): REDUCED DERIVATIVES
Hydroxyarylmethyl benzazinones

Example	R_1	X	Y	Z	B	Molecule	F°C
6b	CH_3	O	-	H			157-158
7b	H	S	-	H			202-203
8b	CH_3	S	-	H			196-197
9b	CH_2CH_3	S	-	H			146-150
10b	H	CH_2	-	H			178-180
11b	H	O	CH_2	H			180-182
12b	CH_3	O	CH_2	H			unstable

Table III-A (continued): REDUCED DERIVATIVES

Hydroxyarylmethyl benzazinones

Example	R_1	X	Y	Z	B	Molecule	F°C
13b	H	O	CH_2	H			156-160
14b	CH_3	O	CH_2	H			115-118
15b	H	S	CH_2	H			238-240
16b	CH_3	S	CH_2	H			115-118
17b	H	O	-	H			143-144
18b	CH_3	O	-	H			119-120
19b	H	S	-	H			159-160
20b	CH_3	S	-	H			127-129

21b	CH_3	O	-	H			154-155
22b	CH_3	S	-	H			152-155
23b	H	S	-	H			208-212
24b	H	O	CH_2	H			257-260
25b	H	S	CH_2	H			173-179
26b	H	O	-	H			208-212
27b	H	O	-	H			216-220
28b	H	O	-	6-OCH_3			156-157

15

5

Table III-A (continued): REDUCED DERIVATIVES
Hydroxyarylmethyl benzazinones

Example	R_1	X	Y	Z	B	Molecule	F°C
29b	H	O	-	H			153-154
30b	CH_3	O	-	H			127-128
31b	CH_3	O	-	H			149-153
32b	H	O	CH_2	H			132-137
33b	CH_3	O	CH_2	H			117-119

5

Table III-B: REDUCED DERIVATIVES
Hydroxylmethyl benzazinone



Example	R_1	X	Y	Z	B	Isomer	Molecule	F°C
1a	CH_2CH_3	S	-	H		6		160-162
2a	H	Se	-	H		6		209-213
3a	CH_3	Se	-	H		6		205-208
4a	CH_2CH_3	Se	-	H		6		132-134
5a	CH_3	Se	-	H		6		182-183
6a	CH_2CH_3	Se	-	H		6		135-137
7a	CH_3	S	-	H		5		183-186
8a	CH_2CH_3	S	-	H		5		156-158

Table IV



Example	Code	R_1	X	Y	Z	A	B	Molecule	F°C
1	**PCH113**	H	O	-	H				122-126
2	**PCH27**	CH_3	O	-	H				85-87
3	**PCH119**	H	O	-	H				113-117

5

Table IV (continued)

4	**PCH122**	CH_3	O	-	H				185-187
5	**PCH30**	CH_3	O	-	H				66-68
6	**PCH116**	CH_3	O	-	H				60-65
7	**PCH215**	H	S	-	H				214-216
8	**PCH165**	CH_3	S	-	H				105-108

Table IV (continued)

9	**PCH241**	CH_2CH_3	S	-	H				95-98
10	**PCH234**	H	CH_2	-	H				200-209
11	**PCH218**	H	O	CH_2	H				139-143
12	**PCH213**	CH_3	O	CH_2	H				123-125
13	**PCH225**	H	O	CH_2	H				135-140

Table IV (continued)

14	**PCH222**	CH_3	O	CH_2	H				80-87
15	**PCH229**	H	S	CH_2	H				150-155
16	**PCH240**	CH_3	S	CH_2	H				74-80
17	**PCH128**	H	O	-	H				128-132
18	**PCH129**	H	O	-	H				75-80
19	**GCA36**	H	O	-	6-OCH_3				165-160

Table IV (continued)

20	**PCH216**	H	S	-	H				127-130
21	**PCH158**	CH_3	S	-	H				165-168
22	**PCH230**	H	S	CH_2	H				215-218
23	**PCH231**	CH_3	S	CH_2	H				95-100

22

Table IV (continued)

24	**PCH211**	H	O	CH_2	H				203-206
25	**PCH10**	H	O	-	H				193-195
26	**AL22**	CH_3	O	-	H				73-74
27	**PCH15**	CH_3	O	-	H				76-78
28	**PCH21**	CH_3	O	-	H				225-226

23

Table IV (continued)

29	**PCH20**	CH_3	O	-	H				77-79
30	**PCH124**	H	O	-	H				108-111
31	**PCH31**	CH_3	O	-	H				133-135
32	**PCH183**	CH_3	O	-	H				135-138
33	**PCH160**	CH_3	O	-	H				70-74

Table IV (continued)

34	**GCA37**	H	O	-	6-OCH_3				125-130
35	**PCH100**	H	S	-	H				55-60
36	**PCH28**	CH_3	S	-	H				65-68
37	**PCH208**	CH_3	S	-	H				150-154

5

Table IV (continued)

38	**PCH164**	CH_3	S	-	H				106-112
39	**PCH249**	H	S	-	H				238-241
40	**PCH19**	CH_3	O	CH_2	H				66-68
41	**PCH210**	CH_3	O	CH_2	H				160-164
42	**PCH214**	CH_3	O	CH_2	H				140-150
43	**PCH227**	H	S	CH_2	H				187-189

26

5

Table IV (continued)



Example	Code	R_1	X	Y	Z	A	B	Isomer	Molecule	F°C
44	**PCH 243**	CH_2CH_3	S	-	H			6		79-83
45	**PCH 302**	H	Se	-	H			6		223-226
46	**PCH 300**	CH_3	Se	-	H			6		154-158
47	**PCH 303**	CH_2CH_3	Se	-	H			6		95-98

Table IV (continued)

48	**PCH 304**	CH_3	Se	-	H			6		190-195
49	**PCH 305**	CH_2CH_3	Se	-	H			6		79-82
50	**PCH 163**	CH_3	S	-	H			5		122-125
51	**PCH 246**	CH_2CH_3	S	-	H			5		125-127

TABLE V

Results of tests in vitro and in vivo of compounds of formula (I) according to the invention

Code	Compound	*Activiy In vitro* IC_{50} (nM)	% inhibition to doses (μg/Kg)
Letrozole		4.23	66% (1) 57, 59% (1) 74% (3) 91, 86% (5) 90% (10) 94, 89% (10)
(s)-Fadrozole		61 (h) 260 (e)	

5

TABLE V (continued)

BENZOXAZOLINONIC DERIVATIVES			
Benzoxazolinonic derivatives substituted in position 6			
Code	**Compound**	***Activiy In vitro* IC_{50} (nM)**	**% inhibition to doses**
PCH10		84.63 (h) 103.3 (e)	
AL22		320 (h) 340 (e)	
PCH15		>2000 (h) nd (e)	

TABLE V (continued)

PCH30		38.0 (h) 47.7 (e)	
PCH116		33.7 (h) 34.6 (e)	
PCH113		13.25 (h) 14.6 (e)	19% (10) 50% (100) 94% (1000)
PCH27		46.2 (h) 72 (e)	
PCH119		25.05 (h) 27.7 (e)	

TABLE V (continued)

PCH122		18.63 (h) 23.25 (e)	39% (10) 58% (100) 92% (1000)
PCH21		>3000 (h) nd (e)	
PCH20		>3000 (h) nd (e)	

TABLE V (continued)

Benzoxazolinonic derivatives substituted at position 5			
Code	**Compound**	***Activiy In vitro* IC_{50} (nM)**	**% inhibition to doses (µg/kg)**
PCH124		14.95 (h) 14.1 (e)	34% (10) 71% (100) 92% (1000)
PCH31		46.6 (h) 50.1 (e)	
PCH129		26.8	
PCH128		5.83	29% (1) 29% (10) 53% (100)
GCA36		19.9	

TABLE V (continued)

PCH183		1813	
PCH160		18.7	
PCH195		17.1	
PCH196		24.9	
GCA37		328	

TABLE V (continued)

Benzothiazolinonic derivatives			
Benzothiazolinonic derivatives substituted in position 6			
Code	**Compound**	***ActivityIn vitro* IC_{50} (nM)**	**% inhibition to doses(μg/Kg)**
PCH100		33.65 (h) 34.0 (e)	
(+/-) PCH28		12.1 (h) 23.4 (e)	13% (10) 25% (100) 75% (1000)
(E1) PCH28		24.35 (h) 24.9 (e)	
(E2) PCH28		26.43 (h) 22.6 (e)	
PCH215		4.04	0% (1) 56% (10) 90% (100)

TABLE (V) continued

PCH165 (+/-)CD4		4.54	22% (1) 23% (10) 66% (100)
PCH165 (+)CD4		8.81	
PCH165 (-)CD4		4.94	
PCH241		4.29	18% (1) 37% (3) 16% (10)
PCH216		7.51	21% (1) 32% (10) 76% (100)
PCH158 (PCH190)		8.71	54, 60% (1) 56, 74% (10) 68, 100% (100)
PCH260		4.49	32% (1) 50% (10) 90% (100)

TABLE V (continued)

PCH258		31.7	
PCH259		3.05	31% (1) 63% (10) 88% (100)
PCH243		3.99	
PCH248		11.8	

TABLE V (continued)

Benzothiazolinonic derivatives substituted in position 5			
Code	**Compound**	***Activiy In vitro* IC_{50} (nM)**	**% inhibition to doses(μg/Kg)**
PCH132		178	
PCH134		179	
PCH163		5.78	57% (1) 83% (10) 95% (100)
PCH246		5.51	22% (1) 45% (10) 91% (100)

TABLE V (continued)

Benzoselenazolinonic derivatives			
Selenazolinonic derivatives substituted in position 6			
Code	**Compound**	***Activiy In vitro* IC_{50} (nM)**	**% inhibition to doses (µg/Kg)**
PCH300		4.64	49% (1) 86% (10) 91% (100)
PCH302		6.53	45% (1) 20% (10) 63% (100)
PCH303		3.99	38% (1) 60% (10) 71% (100)

TABLE V (continued)

PCH304		3.64	
PCH305		3.70	

40

TABLE V (continued)

Benzoxazinonic derivatives			
Benzoxazinonic derivatives substituted at position 7			
Code	**Compound**	***Activiy In vitro* IC_{50} (nM)**	**% inhibition to doses (µg/Kg)**
PCH19		52.48 (h) 59.87 (e)	
PCH211		74.4	

TABLE V (continued)

Code	Compound	*Activiy In vitro* IC_{50} (nM)	% inhibition to doses (μg/Kg)
PCH218		65.5	
PCH213		5.64	0% (1) 3% (10) 5% (100)
PCH225		9.90	
PCH222		3.44	0% (1) 22% (3) 32% (10)
PCH 223			4% (1) 22% (10) 66% (100)

42

TABLE V (continued)

Benzothiazinonic derivatives			
Benzothiazinonic derivatives substituted in position 7			
Code	**Compound**	***Activiy In vitro* IC_{50} (nM)**	**% inhibition to doses (µg/Kg)**
PCH227		55.1	
PCH229		13.8	11% (10) 42% (100) 83% (1000)
PCH240		5.38	

TABLE V (continued)

PCH230		34.8	2% (10) 22% (100) 74% (1000)
PCH231		56.6	